Researchers Identify Potential Modifier Genes in Patients with Charcot-Marie-Tooth Disease
Gene modifiers may explain why symptoms and severity vary in CMT and other inherited diseases, according to research published in JND
June 18, 2019
Amsterdam, NL – Charcot-Marie-Tooth (CMT) disease is the most common inherited neurological disorder affecting peripheral motor and/or sensory nerves in humans. Monogenic disorders like CMT1A, CMT’s most prevalent subtype, are caused by a single gene defect. However, its clinical presentation and severity can vary widely, leading doctors to wonder what factors might be responsible for these differences. A study published in the Journal of Neuromuscular Diseases reveals that while all patients with CMT1A share a single gene defect, at least four clinical characteristics were found to be associated with secondary modifying genes.
“Modifier studies offer a significant pathway to additional therapeutic target discovery and underscore that monogenic disorders are a lot more complex than previously thought,” explained lead investigator Stephan Züchner, MD, PhD, of the Department of Human Genetics and Hussman Institute for Human Genomics of the University of Miami, USA. “Our study is a first in CMT, and one of the largest in all of rare diseases, to explore – genome wide and unbiased – the correlation of clinical outcome and genetic modifier loci. This study also proves the feasibility of this approach and should encourage scientists to pursue data aggregation and standardized protocols in rare disease in order to obtain a much more complete picture of the genetic architecture of rare disorders.”
The study focused on close to 1,000 patients of European ancestry with CMT1A enrolled in a standard protocol over nine years. Researchers genotyped more than 600,000 genomic markers using DNA samples from these patients and performed a case-only genome-wide association study (GWAS) to identify potential genetic association with particular clinical outcomes in a subset of 644 individuals of European ancestry.
Researchers searched for single nucleotide polymorphisms (SNPs), which are specific variations at a single position in a DNA sequence among individuals. Then they investigated whether the SNPs could be statistically associated with any of 14 clinical manifestations of CMT1A, such as disease severity, using the CMT neuropathy score (CMTNS), motor symptoms, sensory symptoms, muscle strength, foot deformity, scoliosis, and hearing loss. “This allowed us to screen genome wide for markers that indicate a correlation with particular clinical outcomes,” said Dr. Züchner.
We identified significant genomic loci that contained candidate genes. Four “subphenotypes” of CMT1A (difficulty with using eating utensils, hearing loss, decreased ability to feel, and CMTNS score) were found to be associated with particular SNPs or chromosomal regions. For example, hearing loss affected 16% of 364 individuals. In these individuals, “suggestive associations signals” were found on chromosome 5. The association signal was supported by multiple SNPs around a lead SNP. Other nearby genes were also found to be affected, none of which had previously been implicated in hearing loss.
“This is still a high-level statistical exploration and the benefit for individual patients is not yet fully understood. In the best-case scenario, we will be able to use such modifier genetic information to predict more precisely the natural course of disease in a single person,” commented Dr. Züchner. “As new genetic therapies and small molecular screening technologies mature, such targets can be exploited much faster.”
The investigators anticipate that GWAS analysis can be applied to other inherited disorders in order to provide a more nuanced understanding of all genetic anomalies that might contribute to the disease.
According to the Muscular Dystrophy Association, CMT1A accounts for around 60% of CMT1 cases. It is an autosomal dominant demyelinating form of CMT. CMT1 is characterized by muscle weakness, atrophy, and changes in sensation, mostly in the periphery of the body – particularly in the feet, lower legs, hands and forearms. CMT1A patients usually present with CMT symptoms during adolescence but remain ambulatory with no reduced life expectancy.
NOTES FOR EDITORS
Full open access study: “Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study,” by Feifei Tao, Gary W. Beecham, Adriana P. Rebelo, Susan H. Blanton, John J. Moran, Camila Lopez-Anido, John Svaren, Lisa Abreu, Devon Rizzo, Callyn A. Kirk, Xingyao Wu, Shawna Feely, Camiel Verhamme, Mario A. Saporta, David N. Herrmann, John W. Day, Charlotte J. Sumner, Thomas E. Lloyd, Jun Li, Sabrina W. Yum, Franco Taroni, Frank Baas, Byung-Ok Choi, Davide Pareyson, Steven S. Scherer, Mary M. Reilly, Michael E. Shy, Stephan Züchner, and the Inherited Neuropathy Consortium, published in the Journal of Neuromuscular Diseases, Volume 6, Issue 2 (2019) by IOS Press (DOI: 10.3233/JND-190377). The article is openly available at: content.iospress.com/articles/journal-of-neuromuscular-diseases/jnd190377.
This research was supported by NIH grants (R01NS43174, U54NS065712, R01NS075764, R01NS075269, U54HD090256, R01NS094388), the Charcot-Marie-Tooth Association, the Muscular Dystrophy Association, the Medical Research Council grant (G0601943), the National Institute of Neurological Diseases and Stroke, Office of Rare Diseases (U54NS065712), and the National Institute for Health Research, University College London Hospitals Biomedical Research Centre.
Contact Diana Murray, IOS Press (+1 718-640-5678 or email@example.com) for additional information. Journalists who wish to interview the authors should contact Stephan Züchner (+1 305 243 2281 or SZuchner@med.miami.edu).
About the Journal of Neuromuscular Diseases
The Journal of Neuromuscular Diseases (JND) facilitates progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias, and myositis). The journal publishes research reports, reviews, and short communications. Guided by Editors-in-Chief Carsten G. Bönnemann (National Institute of Neurological Disorders and Stroke, NIH) and Hanns Lochmüller (Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada), JND is dedicated to providing an open forum for original research in basic science, translational, and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases. iospress.com/journal-of-neuromuscular-diseases
About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 80 international peer-reviewed journals and about 75 book titles each year on subjects ranging from computer science, artificial intelligence, and engineering to medicine, neuroscience, and cancer research. iospress.com